Connect with us


InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF) Updates Pain Program



InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF) reported additional pre-clinical data in the advancement of INM-405 for the cure of pain. In recent pre-clinical assessment, the company employed numerous methods to substantiate the effects of individual, non-THC cannabinoids, and a matrix of cannabinoid combinations, offered to cure peripheral pain.

These methods include in vivo animal models of pain to estimate the pain tolerance; in vivo behavioral trials to verify the CNS related side effects; and in vivo electrophysiology recordings to know the blockage of pain signal spread in the peripheral nerve fibres.

The highlights

Results from the recent data indicate that peripheral application of specific cannabinoid compounds, in combination or alone, is effective in the cure of craniofacial muscle pain disorders, with no CNS side effects noted, and may be a more desirable plan as compared to systemic pain-relief administration.

Previously, InMed announced the expression of both CB2 and CB1 receptors in trigeminal ganglion neurons stimulating the masseter muscle, offering indication that these receptors can be marks for craniofacial muscle pain. CB2 and CB1 receptors are main targets in the body for cannabinoid medications.

There is a requirement to find options to treat severe and chronic pain that have limited side effects and are non-addictive. InMed continues to work upon the potential of non-THC Hemps to treat pain utilizing a topical formulation. The company’s proof of concept trial data published in the European Journal of Pain this July, showcased the topical use of THC to successfully cure peripheral pain.

Recently, the company submitted a provisional patent application in the U.S. for INM-405 and other innovative compositions as Hemp-based topical therapies for the cure of pain, which is a vital step in safeguarding InMed’s commercial and intellectual property. The base of this patent is the unreported results, mentioned above, on non-THC Hemps and their ability to regulate pain. The patent mentions a range of Hemps, alone or in combination, smeared topically to treat several types of pain – nerve, arthritis-induced joint pain, muscle, etc.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.